Biothera Expands Clinical Advisory Board

World Renowned Oncologists to Assist Clinical Development Program
EAGAN, Minn.--(Business Wire)--
Three world-renowned oncologists have joined the Biothera Clinical Advisory
Board, the company announced today.

Dr. Roy Herbst, M.D. Anderson Cancer Center; Dr. Jerome Ritz, Dana-Farber Cancer
Institute; and Dr. Leonard Saltz, Memorial Sloan-Kettering Cancer Center; will
assist with the clinical development program of Imprime PGG®, a
non-chemotherapeutic drug that enhances monoclonal antibody efficacy through
targeted innate immune cell activation.

“Together with our existing board members, we are extremely pleased to have the
best minds in the field of oncology help guide our clinical development
efforts,” said Daniel K. Conners, Biothera chairman and founder. “Their
commitment to Biothera is a testament to the exciting potential of our
technology.”

A brief bio of each new clinical advisory board member follows:

Roy S. Herbst, M.D., Ph.D.
M.D. Anderson Cancer Center

Dr. Herbst is Professor of Medicine and Chief of Section of Thoracic Medical
Oncology at the University of Texas M.D. Anderson Cancer Center in Houston. He
received his Ph.D. in Molecular Cell Biology from Rockefeller University, his
M.D. from Cornell University Medical College and master degrees from Harvard
Medical School in Clinical Investigation/Medical Science. His research focus is
on the diagnosis and treatment of lung cancers.

Jerome Ritz, M.D.
Dana-Farber Cancer Institute

Dr. Ritz is Professor of Medicine, Harvard Medical School; Professor of
Medicine, Dana-Farber Cancer Institute; and Director, Cell Manipulation Core
Facility, Dana-Farber Harvard Cancer Center, Boston. Dr. Ritz received his M.D.
from Chicago Medical School, followed by residency in internal medicine at the
University of Wisconsin Hospitals, Madison. He completed a clinical fellowship
in hematology and oncology at Beth Israel Hospital, and a research fellowship at
Dana-Faber Cancer Institute. Dr. Ritz also has a M.A. from Harvard University.

Leonard B. Saltz, M.D.
Memorial Sloan-Kettering Cancer Center

Dr. Saltz is a Member of Memorial Sloan-Kettering Cancer Center and Attending
Physician at Memorial Hospital for Cancer and Allied Diseases, New York, NY. A
Professor of Medicine at Cornell University’s Weill College of Medicine, Dr.
Saltz is an internationally recognized expert in the development of new
treatments for colorectal cancer. He received his doctorate from Yale University
School of Medicine and completed residencies at The New York Hospital/Cornell
Medical Center. Dr. Saltz completed fellowships at The New York Hospital/Cornell
Medical Center, The Rockefeller University. He was instrumental in the
development of Erbitux®, a monoclonal antibody from ImClone Systems.

Existing members of the Biothera Clinical Advisory Board are:

Dr. Arkadiusz Dudek, M.D., Ph.D.
University of Minnesota

Dr. Dudek is an Associate Professor of Medicine and Director of the Clinical
Trials Office in the Hematology, Oncology and Transplantation Division at the
University of Minnesota. He received his M.D. from the Medical University of
Warsaw, Poland. Dr. Dudek completed his internal medicine residency in
Harrisburg, Pennsylvania and subspecialty training in Hematology, Oncology and
Transplantation at the University of Minnesota. He received his Ph.D. from
Military Medical Academy of Warsaw.

Michael R. Kurman, M.D.
Michael Kurman Consulting

Dr. Kurman is President of Michael Kurman Consulting and advises numerous
pharmaceutical development companies, including Avalon Pharmaceuticals, Thallion
Pharmaceuticals and Locus Pharmaceuticals. He previously held several senior
clinical research positions at Quintiles, US Bioscience and Cytogen Corporation.
Dr. Kurman received his M.D. from Cornell University Medical College.

Richard H. Patt, M.D.
Foresight Consulting

Dr. Patt has more than 15 years of experience as both an academic and clinical
radiologist, in managed care, and in directing clinical development programs.
Dr. Patt was Director, Magnetic Resonance Imaging at Georgetown University
Medical Center and Assistant Professor of Radiology. He has been internationally
recognized for his research using MRI for breast cancer detection, and served on
the National Cancer Institute (NCI) Breast MRI Advisory Board. Dr. Patt received
his M.D. from Georgetown University School of Medicine, where he completed both
his radiology residency and subspecialty fellowship.

“The advice and counsel of these leaders in oncology and radiology will be a
significant benefit to Biothera in the development of Imprime PGG,” said
Conners.

Imprime PGG is a novel immunotherapy that works in concert with anti-tumor
monoclonal antibodies to activate a large population of the body’s innate immune
cells to kill cancer cells. As a platform therapeutic in oncology, Imprime PGG
has the potential to improve patient response rates for existing monoclonal
antibody therapies in approved indications, create new indications for these
drugs and enhance the efficacy of development-stage monoclonal antibody drugs.

Imprime PGG has demonstrated a strong safety profile in multiple Phase I
clinical trials. Biothera is currently conducting a dual-arm, open-label Phase
Ib/IIa clinical trial in metastatic colorectal cancer patients in combination
with Erbitux with and without chemotherapy. Biothera is also commencing two
Phase II studies in Non Small Cell Lung Cancer patients in early 2009. One trial
will evaluate Imprime PGG in combination with Avastin® and chemotherapy and the
other will study Imprime PGG in combination with Erbitux and chemotherapy.

About Biothera, the Immune Health Company

Biothera is a biotechnology company dedicated to improving immune health. The
company is developing pharmaceuticals that target, direct and activate the
innate immune system to fight cancer. (www.biothera.com)

Biothera, the Immune Health Company
David Walsh, 651-256-4606 (direct)
VP Communications
dwalsh@biothera.com

Copyright Business Wire 2008